Expression of human papillomavirus E6 and E7 oncoprotein mRNA in women with low-grade squamous intraepithelial lesions or less

Casagrande, D C; Ribalta, Julisa Chamorro Lascasas; Leite, K D P F; Schimidt, Manoel; Speck, Neila Maria de Góis

doi:10.4238/gmr.15017916

Cited by 4 publications

(3 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is well noted that the expression of viral oncogenes E6/E7 in HPV‐infected premalignant and malignant cells plays an important role in high‐grade CIN formation and tumorigenesis . Consistent with those opinions, our studies revealed that REBACIN® treatment led to significant regression of HPV‐induced CIN1; moreover, our preliminary data indicated that REBACIN® treatment also had strong effect on cervical lesion regression in CIN2 patients.…”

Section: Discussionsupporting

confidence: 90%

“…It is well noted that the expression of viral oncogenes E6/E7 in HPV-infected premalignant and malignant cells plays an important role in high-grade CIN formation and tumorigenesis. [44][45][46][47][48] Consistent with those opinions, our studies revealed that REBACIN ® treatment led to significant regression of HPV-induced CIN1; moreover, our preliminary data indicated that REBACIN ® treatment also had strong effect on cervical lesion regression in CIN2 patients. REBACIN ® showed notable 86.7% (13/15) efficacy in regression of high-grade cervical lesion, and 93.3% (14/15) efficacy in HPV infection clearance after one course treatment (Supporting Information Table S5).…”

Section: Discussionsupporting

confidence: 88%

See 1 more Smart Citation

REBACIN® as a noninvasive clinical intervention for high‐risk human papillomavirus persistent infection

Yang

Duan

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

The development of highly sensitive HPV‐genotyping tests has opened the possibility of treating HPV‐infected women before high‐grade lesions appear. The lack of efficient intervention for persistent high‐risk HPV infection necessitates the need for development of novel therapeutic strategy. Here we demonstrate that REBACIN®, a proprietary antiviral biologics, has shown potent efficacy in the clearance of persistent HPV infections. Two independent parallel clinical studies were investigated, which a total of 199 patients were enrolled and randomly divided into a REBACIN®‐test group and a control group without treatment. The viral clearance rates for the REBACIN® groups were 61.5% (24/39) and 62.5% (35/56), respectively, for the two independent parallel studies. In contrast, the nontreatment groups showed self‐clearance rates at 20.0% (8/40) and 12.5% (8/64). We further found that REBACIN® was able to significantly repress the expression of HPV E6 and E7 oncogenes in TC‐1 and Hela cells. The two viral genes are well known for the development of high‐grade premalignancy lesion and cervical cancer. In a mouse model, REBACIN® was indicated to notably suppress E6/E7‐induced tumor growth, suggesting E6 and E7 oncogenes as a potential target of REBACIN®. Taken together, our studies shed light into the development of a novel noninvasive therapeutic intervention for clearance of persistent HPV infection with significant efficacy.

show abstract

Section: Discussionsupporting

confidence: 90%

Section: Discussionsupporting

confidence: 88%

REBACIN® as a noninvasive clinical intervention for high‐risk human papillomavirus persistent infection

Yang

Duan

et al. 2019

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…Moreover, in all subjects with negative molecular test result, i.e. with no expression of the genetic material, the Pap test result was also within the normal range -NILM (negative for intraepithelial lesion and malignancy) [25].…”

Section: Discussionmentioning

confidence: 82%

Sensitivity and specificity of hr hPV E6/E7 mrna test in detecting cervical squamous intraepithelial lesion and cervical cancer

Pruski

Przybylski

Lewek³

et al. 2019

Ginekol Pol

View full text Add to dashboard Cite

Objectives: The paper assess the relevance of HR HPV E6/E7 mRNA test in women with abnormal Pap results. Material and methods: Between 2013-2014, 125 women were subjects to the enhanced diagnostics due to abnormal Pap results. According to The Bethesda system, if ASC-US, AGC, LSIL, ASC-H, HSIL or cancer cells were present, the result was abnormal. The patients underwent the enhanced diagnostics which included the following procedures: Pap smear collection for molecular assessment of HR HPV E6/E7 mRNA test, the colposcopic examination and biopsy of clinically suspicious areas. Results: High-grade squamous intraepithelial lesions constituted the most frequent cervical pathology in women with abnormal Pap test results, as well as with the positive results of HR HPV E6/E7 mRNA test. Test sensitivity in patients with the histopathological diagnosis of high-grade squamous intraepithelial lesion was estimated at 86.1%. Conclusions: HR HPV E6/E7 mRNA test identifying neoplastic lesions and cervical cancer is characterised by a high relevance which is reflected by means of sensitivity and specificity. In fact, test sensitivity and specificity increased with the age in the group of patients up to 50 years old.

show abstract

Comparative Efficacy of HPV 16/18 DNA and E6/E7 mRNA Testing in Detecting High-Grade Cervical Lesions (CIN2+) in Women with Cervical Biopsies

Benvari,

Aslanimehr,

Samiee-Rad

et al. 2024

Diagnostic Microbiology and Infectious Disease

View full text Add to dashboard Cite

Expression of human papillomavirus E6 and E7 oncoprotein mRNA in women with low-grade squamous intraepithelial lesions or less

Cited by 4 publications

References 38 publications

REBACIN® as a noninvasive clinical intervention for high‐risk human papillomavirus persistent infection

REBACIN® as a noninvasive clinical intervention for high‐risk human papillomavirus persistent infection

Sensitivity and specificity of hr hPV E6/E7 mrna test in detecting cervical squamous intraepithelial lesion and cervical cancer

Comparative Efficacy of HPV 16/18 DNA and E6/E7 mRNA Testing in Detecting High-Grade Cervical Lesions (CIN2+) in Women with Cervical Biopsies

Contact Info

Product

Resources

About